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ABSTRACT Infections due to carbapenemase-producing Gram-negative pathogens
are associated with limited treatment options and consequently lead to increased
mortality and morbidity. In response, combinations of existing -lactams and novel
-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have been devel-
oped as alternative treatment options. To understand the development of resistance
and evolutionary trajectories under CAZ-AVI exposure, we studied the effects of cef-
tazidime (CAZ) and CAZ-AVI on the carbapenemase OXA-48 and the epidemic
OXA-48 plasmid in Escherichia coli. Exposure of CAZ and CAZ-AVI resulted in single
(P68A) and double (P68A,Y211S) amino acid substitutions in OXA-48, respectively.
The antimicrobial susceptibility data and enzyme kinetics showed that the P68A sub-
stitution was responsible for an increased activity toward CAZ, whereas P68A,Y211S
led to a decrease in the inhibitory activity of AVI. X-ray crystallography and molecu-
lar modeling of the mutants demonstrated increased flexibility within the active site,
which could explain the elevated CAZ hydrolysis and reduced inhibitory activity
of AVI. Interestingly, these substitutions resulted in collateral effects compromis-
ing the activity of OXA-48 toward carbapenems and penicillins. Moreover, expo-
sure to CAZ-AVI selected for mutations within the OXA-48-encoding plasmid that
severely reduced fitness in the absence of antimicrobial selection. These evolu-
tionary trade-offs may contribute to limit the evolution of OXA-48-mediated CAZ
and CAZ-AVI resistance, as well as potentially resensitize isolates toward other
therapeutic alternatives.
IMPORTANCE The recent introduction of novel -lactam/-lactamase inhibitor
combinations like ceftazidime-avibactam has increased our ability to treat infec-
tions caused by multidrug-resistant Gram-negative bacteria, including carba-
penemase-producing Enterobacterales. However, the increasing number of cases
of reported resistance to ceftazidime-avibactam is a concern. OXA-48 is a carbap-
enemase that has no significant effect on ceftazidime, but is inhibited by avibac-
tam. Since isolates with OXA-48 frequently harbor extended-spectrum
-lactamases that are inhibited by avibactam, it is likely that ceftazidime-
avibactam will be used to treat infections caused by OXA-48-producing Entero-
bacterales. Our data show that exposure to ceftazidime-avibactam can lead to
changes in OXA-48, resulting in increased ability to hydrolyze ceftazidime and
withstand the inhibitory effect of avibactam. Thus, resistance toward ceftazidime-
avibactam among OXA-48-producing Enterobacterales should be monitored. In-
terestingly, the compromising effect of the amino acid substitutions in OXA-48
on other -lactams and the effect of ceftazidime-avibactam exposure on the epi-
demic OXA-48 plasmid indicate that the evolution of ceftazidime-avibactam re-
sistance comes with collateral effects.
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The increasing rates of carbapenem resistance among Gram-negative pathogens isconsidered a critical public health threat and is associated with significant morbid-
ity and mortality (1, 2). Recent estimates indicate that carbapenem-resistant Escherichia
coli and Klebsiella pneumoniae caused 0.5 million bloodstream infections and 3.1 million
serious infections worldwide in 2014 (3). A major contributor to carbapenem resistance
is the acquisition of plasmid-mediated -lactamases (carbapenemases), enabling the
inactivation of carbapenems (4, 5). A wide range of carbapenemases have been
identified among carbapenemase-producing Enterobacterales (CPE), including the ser-
ine -lactamases KPC (Ambler class A) and OXA-48-like (Ambler class D), as well as the
metallo--lactamases NDM, VIM, and IMP (Ambler class B) (6, 7). Since CPE are com-
monly multidrug-resistant, treatment options are limited (8).
Combination therapy with preexisting -lactams and -lactamase inhibitors has
been a successful strategy to overcome the impact of -lactamases, such as extended-
spectrum -lactamases (ESBLs) (9). In line with this approach, the combination of the
third-generation cephalosporin ceftazidime (CAZ) with the novel diazabicyclooctane
non--lactam -lactamase inhibitor avibactam (AVI) (10–12) has recently been devel-
oped and approved for clinical use (13–15). The CAZ-AVI combination has shown
potent activity against CPE isolates since AVI has inhibitory activity toward several
carbapenemases, including KPC and OXA-48 (16). Moreover, AVI also inhibits ESBLs and
class C cephalosporinases, offering a potential treatment option for infections caused
by multidrug-resistant Gram-negative pathogens (16–18). Unfortunately, several re-
ports have now described the emergence of CAZ-AVI resistance in the clinical setting
(19, 20). In a retrospective study at a U.S. medical center, CAZ-AVI resistance emerged
in 8% of the investigated cases (21). A variety of resistance mechanisms causing
CAZ-AVI resistance have been described, including specific amino acid substitutions in
-lactamases such as KPC-2, KPC-3, and CTX-M-14 (22–24) and duplications in OXA-2
(20), as well as deletions of the -loop in AmpC (25). Moreover, CAZ-AVI resistance has
been associated with porin mutations (e.g., OmpK36) (23, 26, 27), efflux activity (23),
and increased -lactamase expression (27). Interestingly, specific amino acid substitu-
tions in KPC and OXA-2 are associated with a collateral effect decreasing the enzymatic
activity toward carbapenems, reversing resistance to these antibiotics (20, 22, 23, 26,
28–31).
In contrast to the majority of carbapenemases, OXA-48-like carbapenemases have
low activity toward carbapenems and show no significant hydrolysis of extended-
spectrum cephalosporins, including CAZ (32, 33). However, some OXA-48-like variants
(e.g., OXA-163, OXA-247, and OXA-405), possess increased hydrolytic activity against
CAZ due to a 4-amino-acid deletion and different single nucleotide polymorphisms
around the 5-6 loop (34–38). Interestingly, these regions have been described as
important for the carbapenemase activity of OXA-48 (32), and increased cephalospo-
rinase activity came with reduced activity toward carbapenems (34–38). In terms of the
epidemiology, OXA-48-producing isolates are increasingly identified in many parts of
the world and are dominating in certain regions, such as North Africa, the Middle East,
and many European countries (1, 34). A major factor for the dissemination of OXA-48
is the strong association with a self-transferable IncL plasmid (39, 40).
To investigate the evolutionary implication of CAZ and CAZ-AVI treatment on
OXA-48-producing isolates, we have studied the effects on both the blaOXA-48 gene and
the epidemic plasmid associated with dissemination of OXA-48. Here, we report the
occurrence of single (OXA-48:P68A) and double (OXA-48:P68A,Y211S) amino acid sub-
stitutions within OXA-48 as a response to CAZ and CAZ-AVI exposure, respectively.
OXA-48:P68A demonstrated increased MICs toward CAZ, and OXA-48:P68A,Y211S
showed increased MICs against both CAZ and CAZ-AVI. X-ray crystallography structures
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revealed that OXA-48:P68A leads to increased flexibility within the OXA-48 structure,
likely contributing to elevated CAZ hydrolysis. Molecular modeling of OXA-48:
P68A,Y211S showed an altered H-bond network due to Y211S. The alteration of this
network is likely to affect the enzyme stability and confer higher CAZ resistance. In
addition, Y211 in OXA-48 stabilizes AVI binding by aromatic stacking. In OXA-48:
P68A,Y211S, the loss of this interaction might contribute to the reduced inhibitory
activity of AVI. However, development of resistance toward CAZ and CAZ-AVI led to
evolutionary trade-offs where (i) amino acid substitutions in OXA-48 compromised its
carbapenemase and penicillinase activities and (ii) plasmid adaptation to CAZ and
CAZ-AVI conferred a significant fitness cost as well as loss of stability.
RESULTS
Selection of mutants with decreased susceptibility toward CAZ and CAZ-AVI.
To investigate how the clinical use of CAZ and CAZ-AVI influences the evolution of
OXA-48, as well as the plasmid carrying OXA-48, we initially subjected a clinical E. coli
strain previously known to carry blaOXA-48 on a conjugative IncL plasmid (34, 35) to
PacBio sequencing. The genomic data revealed that the clinical strain harbored
blaOXA-48 on a 65,499-bp IncL plasmid (p50579417_3_OXA-48; GenBank accession no.
CP033880) with no other resistance genes (see Fig. S1 and reference 73). The plasmid
was closely related to the epidemic IncL OXA-48 plasmid (40) and other OXA-48
plasmids (Fig. S1). We subsequently transferred the plasmid by conjugation into
rifampin-resistant E. coli TOP10, isolated the plasmid, and transformed it into E. coli
MG1655 (MP100 [Table 1]). Due to the lack of cephalosporinase activity of OXA-48, the
introduction of p50579417_3_OXA-48 in E. coli MG1655 (MP101) did not result in any
change in the MICs toward CAZ and CAZ-AVI (Table 2). MP101 was subsequently
subjected to a two-step mutant selection regimen, using increasing concentrations of
CAZ and CAZ-AVI up to 64 the MIC of MP101. Analysis of selected mutants after CAZ
(MP102) and CAZ-AVI (MP103) exposure showed that the MICs toward both CAZ and
CAZ-AVI increased irrespectively of selection regimen (Table 2). With CAZ selection, the
CAZ MIC increased 128-fold and the CAZ-AVI MIC increased 16-fold. Selection with
CAZ-AVI resulted in a 128-fold increase in the MICs for both CAZ and CAZ-AVI (Table 2).
TABLE 1 E. coli strains used and constructed in this study
Strain Description Reference or source
50579417 Host strain of p50579417_3_OXA-48 61, 62
MP100 DA4201 E. coli K-12 MG1655 Uppsala University
MP101 MP100 transformed with p50579417_3_OXA-48 This study
MP102 MP101 subjected to CAZ and host of p50579417_3_OXA-48-CAZ This study
MP103 MP101 subjected to CAZ-AVI and host of p50579417_3_OXA-48-CAZ-AVI This study
TOP10 Recipient strain for pCR-blunt II-TOPO Invitrogen
MP104 E. coli TOP10 transformed with pCR-blunt II-blaOXA-48 This study
MP105 E. coli TOP10 transformed with pCR-blunt II-blaOXA-48-P68A This study
MP106 E. coli TOP10 transformed with pCR-blunt II-blaOXA-48-48-P68A,Y211S This study
MP107 MP100 transformed with p50579417_3_OXA-48-CAZ This study
MP108 MP100 transformed with p50579417_3_OXA-48-CAZ-AVI This study
TABLE 2 MIC after mutant selection of E. coli MG1655 (MP100) expressing OXA-48








aMutants were selected by a two-step selection procedure on plates. Tests were performed in duplicates.
bCAZ, ceftazidime; CAZ-AVI, ceftazidime-avibactam with avibactam fixed at 4 g/ml.
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Amino acid substitutions in OXA-48 cause resistance and collateral effects.
Sequencing of blaOXA-48 after CAZ selection revealed a single mutation, resulting in the
amino acid substitution P68A (OXA-48:P68A). Under CAZ-AVI selection, a double mu-
tant sharing the same amino acid change (P68A) and an additional substitution, Y211S,
was observed (OXA-48:P68A,Y211S). To determine the effect of both the single (P68A)
and double (P68A,Y211S) amino acid substitutions in OXA-48, we cloned the native
blaOXA-48 gene (MP104) and mutated versions into an expression vector in E. coli TOP10.
Subsequent MIC determination revealed that the P68A substitution (MP105) increased
the MIC toward CAZ by 32-fold (Table 3). No change in the MIC toward CAZ-AVI was
observed. For the P68A,Y211S (MP106), the MIC toward CAZ was increased by 32-fold
and that toward CAZ-AVI was increased by 4-fold.
Changes in OXA-2 and KPC-2/3, leading to CAZ or CAZ-AVI resistance, respectively,
have been shown to come along with functional constraints (20, 26, 29, 31). Therefore,
we performed MIC testing against a panel of -lactams. Both the OXA-48:P68A and
P68A,Y211S substitutions caused altered effects toward other -lactams compared to
the native OXA-48 (Table 3). The effect against carbapenems was equal for both the
single and double amino acid substitution, with a 4- to 16-fold decrease in the MIC
against meropenem, imipenem, and ertapenem (Table 3). No change in MIC toward
doripenem was observed. Moreover, expression of both mutants of OXA-48 resulted in
reduced activity against piperacillin-tazobactam (32-fold MIC decrease) and temocillin
(4- to 8-fold MIC decrease). For other -lactams, including other cephalosporins such as
cefepime and cefotaxime, the changes were within a 2-fold dilution step (nonsignifi-
cant).
Thermostability and enzyme kinetics of OXA-48:P68A and OXA-48:
P68A,Y211S. OXA-48, OXA-48:P68A, and OXA-48:P68A,Y211S were expressed and
purified (95% purity). From an initial starting culture of 1 liter, yields of 23.9, 9.9, and
16.7 mg, respectively, were obtained. P68A and P68A,Y211S caused a reduction in the
thermostability of OXA-48, with melting temperatures of 49.5  0.1°C and 46.7  0.2°C,
respectively, compared to 53.5  0.1°C for the native OXA-48. We further determined
the effect of the amino acid changes, with respect to both the hydrolytic activity




TOP10 MP104 MP105 MP106
Penicillins and inhibitor
combinations
TRM 16 256 64 32
TZP 2 64 2 2
AMC 4 128 128 64
Cephalosporins
CAZ 1 0.5 16 8
CAZ-AVI 0.25 0.25 0.25 1
CXM 16 16 16 16
FEP 0.06 0.12 0.25 0.12
FOT 0.12 0.25 0.25 0.12
Carbapenems
MEM 0.03 0.25 0.03 0.03
IMI 0.25 1 0.25 0.25
ETP 0.015 1 0.06 0.06
DOR 0.03 0.03 0.03 0.03
aTRM, temocillin; TZP, piperacillin-tazobactam with tazobactam fixed at 4 g/ml; AMC, amoxicillin-clavulanic
acid with clavulanic acid fixed at 2 g/ml; CAZ, ceftazidime; CAZ-AVI, ceftazidime-avibactam, with avibactam
fixed at 4 g/ml; CXM, cefuroxime; FEP, cefepime; FOT, cefotaxime; MEM, meropenem; IMI, imipenem; ETP,
ertapenem; DOR, doripenem.
bShown are the MICs of E. coli TOP10 and corresponding strains expressing native OXA-48, OXA-48:P68A, and
OXA-48:P68A,Y211S (MP104, MP105 and MP106, respectively). For expression, genes were subcloned into
the pCR-blunt II TOPO vector. Tests were performed in duplicates.
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against -lactams as well as the inhibitory effect (50% inhibitory concentration [IC50])
of AVI and tazobactam. Compared to native OXA-48, P68A and P68A,Y211S caused
10-fold and 20-fold increased catalytic efficiency (kcat/Km) toward CAZ, respectively
(Table 4). In addition, both substitutions conferred reduced hydrolytic activity toward
penicillins (ampicillin and piperacillin) and carbapenems (imipenem and meropenem
[Table 4]). The reduced catalytic efficiency varied from 2- to 600-fold compared to the
native OXA-48. No change was observed for the cephalosporin cefepime.
For OXA-48:P68A, we observed no change in the inhibitory activity of AVI (Table 5).
However, the double substitution P68A,Y211S resulted in a 5-fold decrease in inhib-
itory activity of AVI. Moreover, both the P68A and P68A,Y211S substitutions led to an
increased inhibitory activity of tazobactam with 20-fold and 3-fold reductions in the
IC50 compared to the native OXA-48 (Table 5).
P68A and P68A,Y211S increase flexibility of the active site. Two new crystal
structures of OXA-48:P68A were obtained after soaking (see Table S1 in the supple-
mental material). Both structures displayed four molecules in the asymmetric unit
arranged in two dimers (chains A to D). In the first OXA-48:P68A structure (resolved to
2.50 Å), we found CAZ bound to chain A/C (OXA-48:P68A-CAZ), as well as two empty
active sites (chain B/D, OXA-48:P68A)—thus, one CAZ molecule per dimer. The second
OXA-48:P68A structure was in complex with AVI (OXA-48:P68A-AVI) and resolved to
2.22 Å. The effect of the amino acid change P68A was studied by superimposing the
unbound chains B and D (OXA-48:P68A) onto native OXA-48 (PDB no. 4S2P) (10) which
demonstrated similar conformations (Fig. 1A) and an insignificant root mean square
deviation (RMSD) of 0.3 Å. In chains A and C of OXA-48:P68A-CAZ, CAZ was found
covalently bound to the active-site residue S70 and stabilized by H-bonds involving
residues S70, T209, Y211, S212, T213, R214, and R250 (Fig. 1B). Comparing the CAZ
unbound and bound chains of OXA-48:P68A, several conformational changes were
evident.
CAZ binding forces R214 in the 5-6 loop to move out of the active site. As a result,
R214 would then clash with parts of the -loop (D143 to S165) in the native OXA-48
(Fig. 1B). Indeed, we found residues 149 to 161 (for both chains A and C) in the -loop
of OXA-48:P68A to be disordered (Fig. 1B) and thus not visible in the electron density
maps. Therefore, P68A seems to impose increased flexibility within OXA-48, and this
enables both the 5-6 loop and -loop to occupy alternative conformations and
TABLE 4 Kinetic values of recombinantly expressed and purified OXA-48, OXA-48:P68A, and OXA-48:P68A,Y211Sa
Substrateb
OXA-48 OXA-48:P68A OXA-48:P68A,Y211S
Km (M) kcat (s1)
kcat/Km
(s1 mM1) Km (M) kcat (s1)
kcat/Km
(s1 mM1) Km (M) kcat (s1)
kcat/Km
(s1 mM1)
AMP 370  70 608  53 1,643  455 77  12 25  1 331  66 211  26 18  1 86  14
PIP 898  155 3.9  0.5 4  1 290  67 0.15  0.02 0.5  0.2 155  38 0.06  0.01 0.4  0.2
NIT 226  34 141  12 624  148 53  8 37  2 703  149 63  9 12  1 193  40
CAZ 300  150 3.0  0.8 10  8 220  50 26  3 117  41 190  40 42  5 220  72
FEP 1,678  686 1.7  0.6 1.0  0.8 462  126 0.5  0.1 1.2  0.5 1,459  635 1.1  0.4 0.8  0.6
IMI 13  2 4.8  0.2 365  71 4.2  0.9 0.80  0.04 190  50 14  3 0.57  0.04 41  11
MEM 4  1 0.71  0.02 177  50 3  1 (8  0.8)  104 0.3  0.1 2  1 (2  0.2)  103 1.2  0.7
aErrors are displayed as 95% confidence intervals based on a minimum of triplicates.
bAMP, ampicillin; PIP, piperacillin; NIT, nitrocefin; CAZ, ceftazidime; FEP, cefepime; IMI, imipenem; MEM, meropenem.






Tazobactam 95  9 4  1 31  5
Avibactam 2.2  0.6 1.3  0.3 13  3
aIC50s (50% inhibitory concentrations) were determined using nitrocefin as a reporter substrate. Enzymes and
inhibitor were incubated together for 5 min. Errors are displayed as 95% confidence intervals.
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FIG 1 Crystal structure of OXA-48:P68A and molecular modeling of OXA-48:P68A,Y211S. (A) Structure in the absence of CAZ (red)
superimposed onto native OXA-48 (gray; PDB no. 4S2P) (10). (B) Structure of OXA-48:P68A (gray) in the absence of CAZ (left) and with
CAZ covalently bound (right [CAZ is displayed in orange]). CAZ binding causes a displacement of R214 (red) as well as a disorder of
the -loop. (C) Superimposition of OXA-48:P68A-AVI (red) with native OXA-48 binding AVI (gray; PDB no. 4S2P) (10). In both native
OXA-48 and OXA-48:P68A, we found AVI interacting and binding to the same residues. (D) Superimposition of OXA-48:P68A (gray)
binding CAZ (orange) with the modeled structure of OXA-48:P68A,Y211S (red). Here Y211 and T234, P235, and M236 form H-bonds
with a central coordinated water molecule. Formation of the same H-bonds in the presence of S211 in OXA-48:P68A,Y211S is unlikely.
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consequently favors CAZ binding. Interestingly, the 5-6-loop region has been shown
to be relevant for the carbapenemase versus ceftazidimase activity of OXA-48 (32, 41).
Furthermore, we found AVI covalently bound to S70 in all OXA-48:P68A-AVI chains.
Superimposition of OXA-48:P68A-AVI with the structure of native OXA-48 in a complex
with AVI (PDB no. 4S2K) (11) showed no difference in interaction with AVI (Fig. 1C). R214
and the -loop were in the same conformation as in the native OXA-48.
Crystallization of OXA-48:P68A,Y211S was unsuccessful; therefore, we used molec-
ular modeling and superimposed the obtained structure onto the structure of OXA-
48:P68A-CAZ. In native OXA-48 (PDB no. 4S2P) and OXA-48:P68A, the Y211 side chain
is part of a water-mediated H-bond network, including T234, P235, and M236, where
the water molecule is centrally coordinated (Fig. 1D). In contrast, the formation of this
H-bond network seems not feasible with serine at position 211. In principle, this could
lead to a higher flexibility within the structure of OXA-48:P68A,Y211S and could be
related to the 4°C reduced thermostability, as well as to elevated CAZ hydrolysis,
compared to OXA-48:P68A.
Effect of plasmid adaptations on resistance and host fitness. In order to inves-
tigate the effect of selection on the plasmid backbone, we isolated and transformed the
plasmids after CAZ (p50579417_3_OXA-48-CAZ) and CAZ/AVI (p50579417_3_OXA-48-
CAZ-AVI) selection into MP100. MIC determination of the resulting strains MP107 and
MP108 mirrored the fold changes observed in the cloned expression vector system
(Table 6; see Fig. S2 in the supplemental material). This indicates that the P68A and
P68A,Y211S in OXA-48 are the main contributors to the altered susceptibility profiles.
To further investigate the role of the plasmid during resistance development, we
measured the fitness costs of MP101, MP107, and MP108 in head-to-head competition
assays. The native OXA-48 plasmid did not significantly reduce fitness (relative fitness
[w]  1.01, P  0.509, df  6) in MP101 relative to the plasmid-free strain MP100.
However, after CAZ-AVI adaptation, MP103 showed severely reduced fitness, by 18%
(w  0.82, P  0.008, df  3) relative to the plasmid-free strain MP100 (Fig. 2).
In an attempt to isolate the fitness effects conferred by the plasmids after
adaptation alone, we competed MP107 and MP108 with the native OXA-48 plasmid-





MP100 MP101 MP107 MP108
Penicillins and inhibitor
combinations
TRM 8 256 128 32
TZP 8 128 128 128
AMC 2 64 4 4
Cephalosporins
CAZ 0.25 0.25 16 32
CAZ-AVI 0.12 0.12 0.25 4
CXM 8 16 16 8
FEP 0.06 0.25 0.5 0.25
FOT 0.12 0.5 1 0.25
Carbapenems
MEM 0.03 0.25 0.06 0.06
IMI 0.12 1 0.25 0.25
ETP 0.015 1 0.25 0.12
DOR 0.015 0.03 0.03 0.03
aTRM, temocillin; TZP, piperacillin-tazobactam with tazobactam fixed at 4 g/ml; AMC, amoxicillin-clavulanic
acid with clavulanic acid fixed at 2 g/ml; CAZ, ceftazidime; CAZ-AVI, ceftazidime-avibactam with avibactam
fixed at 4 g/ml; CXM, cefuroxime; FEP, cefepime; FOT, cefotaxime; MEM, meropenem; IMI, imipenem; ETP,
ertapenem; DOR, doripenem.
bShown are the MICs after transformation of E. coli MG1655 (MP100) with the native plasmid (MP101) and
adapted plasmids p50579417-OXA-48-CAZ (MP107) and p50579417-OXA-48-CAZ-AVI (MP108). Tests were
performed in duplicates.
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carrying strain MP101. Both adapted plasmids significantly reduced fitness, by 14%
(p50579417_3_OXA-48-CAZ; P  0.003, df  9) and 3% (p50579417_3_OXA-48-CAZ-
AVI; P  0.026, df  6), respectively. Sequencing of the plasmids after selection revealed
mutational differences on the plasmid backbone. Different point mutations in repA,
79G¡T (p50579417_3_OXA-48-CAZ) and 79G¡T (p50579417_3_OXA-48-CAZ-AVI)
(42), as well as a 62-bp deletion in the DNA binding side of a xenobiotic response
element (transcriptional regulator) in the p50579417_3_OXA-48-CAZ plasmid were
observed. To investigate the effect of CAZ-AVI exposure on OXA-48 plasmid stability,
we serially passaged MP101 harboring the native OXA-48 plasmid and the CAZ-AVI-
exposed strain MP103 for 350 generations under nonselective conditions. Consistent
with the fitness data, the native OXA-48 plasmid was stably maintained throughout the
experiment, whereas loss of p50579417_3_OXA-48-CAZ-AVI was observed after 100
generations. The plasmid was completely lost from the population after 250 gener-
ations (Fig. 3).
DISCUSSION
Treatment options for infections caused by carbapenemase-producing Gram-
negative bacteria are limited, and the increased spread of these multidrug-resistant
bacteria is considered a public health threat (1, 2). Several novel -lactamase inhibitors,
including inhibitors of carbapenemases, have recently been introduced to resurrect the
activity of existing -lactams (43, 44). This includes AVI, a novel diazabicyclooctane
-lactamase inhibitor able to inhibit class A and class D carbapenemases, such as KPC
and OXA-48, respectively. Thus, the introduction of the combination CAZ-AVI offers a
possible treatment option for class A and class D carbapenemase-producing Entero-
bacterales (16). Unfortunately, several reports are now describing the emergence of
CAZ-AVI-resistant Enterobacterales, particularly KPC-producing K. pneumoniae (22, 23,
30). In contrast to carbapenemases such as KPC, the OXA-48 carbapenemase has an
insignificant hydrolysis activity toward third-generation cephalosporins, including CAZ.
However, the CAZ-AVI combination is a promising treatment option since OXA-48-
FIG 2 Mixed head-to-head competitions. Strains were mixed in a 1:1 ratio and grown together
overnight. Ratios before and after incubation were determined by selective plating. For bar 1, MP100 (E.
coli MG1655) competed with MP101 (E. coli MG1655 carrying p50579417_3_OXA-48) demonstrated no
initial cost of the native OXA-48 plasmid. For bar 2, competitions of MP100 (E. coli MG1655) with MP103
(MP101 subjected to CAZ-AVI) resulted in a high fitness cost of 18% for the strain subjected to CAZ-AVI.
For bars 3 and 4, comparisons of MP101 versus MP107 (E. coli MG1655 transformed with
p50579417_3_OXA-48-CAZ) and MP108 (E. coli MG1655 transformed with p50579417_3_OXA-48-CAZ-
AVI) demonstrated significant costs of 14% and 3%, respectively. All measurements were done at least
in triplicates. Statistically significant results are marked with asterisks. Strain abbreviations are listed in
Table 1.
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producing isolates frequently also carry an ESBL (12, 45, 46). Thus, we investigated the
effect of CAZ and CAZ-AVI on the evolution of OXA-48 and an OXA-48 plasmid closely
related to the epidemic IncL plasmid frequently associated with blaOXA-48 (39, 40).
Our results show that both CAZ and CAZ-AVI exposure resulted in mutations in
blaOXA-48 that increased the ability of OXA-48 to hydrolyze CAZ. After CAZ-AVI expo-
sure, we also identified a reduced inhibitory effect of AVI. Moreover, development of
OXA-48 resistance toward CAZ/CAZ-AVI conferred collateral sensitivity where the car-
bapenem and penicillin activities of the enzyme were reduced. Several studies have
reported OXA-48-like variants (OXA-163, OXA-247, and OXA-405) with increased activity
toward extended-spectrum cephalosporins (36–38). These variants carry amino acid
deletions/substitutions within and around the 5-6 loop also leading to reduced
carbapenemase activity. OXA-247 carries the identified Y211S substitution in addition
to a 4-amino-acid deletion (36). From these studies, it was unclear, however, whether
this evolutionary trajectory could have been triggered by the exposure to extended-
spectrum cephalosporins. We show that CAZ and CAZ-AVI have the potential to affect
the evolution of OXA-48 and that the substitutions P68A and P68A,Y211S re-evolve the
function of OXA-48 and specialize the enzyme toward ceftazidime hydrolysis. These
results agree with other studies in which the adaptive changes in enzymes caused
collateral effects, compromising or reversing the original function (20, 29, 31, 47, 48).
While Y211 in OXA-48 is located at the 5-6 loop and is involved in AVI binding by the
formation of an oxyanion hole (11, 32), as well as in aromatic stacking with the side
chain (4.3 Å), the role of P68 in the beginning of the 3 helix is poorly understood.
In silico modeling of OXA variants identified loops flanking the 3 helix to play an
important role for the carbapenemase or CAZ hydrolysis activity in those variants. In
general, increased stability in these loop regions was also correlated with higher affinity
to carbapenems, whereby more flexible loops revealed their catalytic proficiency
toward CAZ (41).
The X-ray structure of OXA-48:P68A with four chains in the asymmetric unit revealed
that CAZ binding requires higher structural flexibility. Generally, CAZ binding resulted
in a displacement of the 5-6 loop carrying R214, as well as a disordered -loop
(Fig. 1B). Docking experiments in OXA-48 have shown that CAZ hydrolysis is mecha-
nistically unfeasible. This is mainly due to the high rigidity and the small active-site
cavity confined by R214, as well as the length of the 5-6 loop (41, 49). In contrast, a
strongly shortened 5-6 loop and the absence of R214, as observed in OXA-163,
expand the active-site cavity and allow OXA-163 to hydrolyze CAZ more efficiently (49).
This supports the hypothesis that P68A increases the flexibility and changes the
plasticity of the substrate binding site in OXA-48, allowing the hydrolysis of bulkier
FIG 3 Plasmid stability of MP101 and MP103 in nonselective MH broth over 350 generations (Table 1).
The native plasmid (p50579417_3_OXA-48) was stably maintained in MP101 over 350 generations
without selection pressure. In the strain subjected to CAZ-AVI, MP103, the adapted plasmid
(p50579417_3_OXA-48-CAZ-AVI) was purged out of the population within 350 generations.
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drugs such as CAZ. Decreased rigidity is also supported by a reduction in thermosta-
bility of 4°C, compared to native OXA-48. Interestingly, OXA-163 (as well as OXA-247
and OXA-405) displayed collateral sensitivity toward carbapenems (36–38, 50) but also
cross-resistance toward some cephalosporins (e.g., cefotaxime). Molecular docking of
OXA-163 suggests that cefotaxime is more embedded within the active site (49).
However, cross-resistance toward other cephalosporins than CAZ was not observed for
the OXA-48:P68A variant. Depending on their R2 side chain, cephalosporins display
different binding behavior in metallo--lactamases (51). While OXA-48:P68A allows CAZ
binding by a displacement of the 5-6 and -loops, we hypothesize that for other
cephalosporins, the active site of OXA-48:P68A might still be too narrow and rigid to
achieve significant hydrolysis.
The double mutant carrying P68A,Y211S conferred a high level of resistance toward
CAZ and elevated MIC levels against CAZ-AVI. Furthermore, P68A,Y211S caused a
20-fold increase in CAZ hydrolysis and a 5-fold reduction in the inhibitory activity of AVI,
compared to native OXA-48. Therefore, our data suggest that OXA-48-mediated devel-
opment of resistance toward CAZ-AVI is due to both increased enzymatic hydrolysis
toward CAZ and reduced inhibitory activity of AVI. Molecular modeling of OXA-48:
P68A,Y211S suggested the alteration of a water-mediated H-bond network between
Y211 OH and T234 O and P235 O and M236 O (Fig. 1D). In OXA-48:P68A,Y211S, S211 is
unlikely to be part of the same H-bond network due to its less-space-filling properties.
The loss of H-bonds can increase enzyme flexibility; however, this is usually accompa-
nied by decreased enzyme stability (52). Indeed, we found OXA-48:P68A,Y211S to be
7°C and 4°C less thermostable compared to native OXA-48 and OXA-48:P68A. We
therefore believe that P68A,Y211S in OXA-48 further increases the flexibility of the
active site, resulting in increased CAZ hydrolysis. In addition, S211 contributes to the
reduced inhibitory activity of AVI by the loss of aromatic stacking, which stabilizes AVI
in OXA-48 and OXA-48:P68A.
In addition, clinically relevant reversion of piperacillin-tazobactam resistance was
shown for both the single and double OXA-48 mutants. Enzyme kinetics also revealed
a double effect where the OXA-48 variants demonstrate reduced piperacillin hydrolysis
activity and stronger inhibition by tazobactam. Similar effects were shown for CAZ-
AVI-mediated mutations within KPC-2 and KPC-3 (29–31). Resensitization through
exploitation of such evolutionary trade-offs could in principle provide the basis for
alternative treatment strategies that potentiate the activities of earlier-generation
-lactams, and several strategies have recently been proposed (53–56).
Since the dissemination of blaOXA-48 is partially linked to closely related IncL
plasmids (39, 40), we wanted to investigate the effect of CAZ and CAZ-AVI exposure on
p50579417_3_OXA-48. Interestingly, the adapted plasmids showed a significant fitness
cost compared to the native plasmid (Fig. 2), as well as reduced plasmid stability
(p50579417_3_OXA-48-CAZ-AVI) in the absence of -lactam selection (Fig. 3). Sequenc-
ing of the CAZ- and CAZ-AVI-exposed plasmids displayed mutations in a regulatory
region (repA) known to be involved in plasmid copy number control (42, 57). Upregu-
lation of plasmid copy number has been shown previously to correlate with both
decreased bacterial fitness and increased drug resistance (58). These data suggest that
P68A and P68A,Y211S mutations, alone or in combination with putative copy number
changes, might negatively impact the fitness of the adapted plasmids.
Mutations in blaKPC-2/3 conferring CAZ-AVI resistance have been observed in the
clinical setting (19, 22, 28, 30, 59). However, to the best of our knowledge, OXA-48-
mediated reduced susceptibility to CAZ-AVI has not yet been reported in clinical
settings (60). This might be due to the evolutionary trade-offs and reduced fitness
reported here, which in principle may limit the occurrence and spread of resistance.
Taken together, our data suggest that CAZ and CAZ-AVI conferred collateral sensitivity
effects where the enzyme compromised its original carbapenemase and penicillinase
activity. In principle, these evolutionary constraints and resensitizations can be ex-
ploited in order to improve future treatment protocols.
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Media, antibiotics, and strains. Mueller-Hinton (MH) agar and broth were purchased from Thermo
Fisher Scientific (East Grinstead, United Kingdom). Luria-Bertani (LB) broth, LB agar, ampicillin, amoxicillin,
cefepime, CAZ, imipenem, meropenem, piperacillin, and tazobactam were obtained from Sigma-Aldrich
(St. Louis, MO). Nitrocefin was purchased from Merck (Darmstadt, Germany). All strains used and
constructed within this study are listed in Table 1. The characteristics of the clinical E. coli strain 50579417
harboring the OXA-48 plasmid (p50579417_3_OXA-48) have been described previously (61, 62). The
plasmid p50579417_3_OXA-48 was conjugated into rifampin-resistant E. coli TOP10 and subsequently
isolated using a plasmid mini-purification kit (Qiagen, Germany). E. coli MG1655 (DA4201) was electro-
porated with p50579417_3_OXA-48 as published previously (63). Transformants positive for blaOXA-48
were checked by PCR using REDTaq ready mix (Sigma-Aldrich, St. Louis, MO) and preOXA-48 primers (61).
PacBio sequencing of E. coli 50579417. Genomic DNA of E. coli 50579417 was prepared from an
overnight culture using the GenElute bacterial genomic DNA kit (Sigma-Aldrich, St. Louis, MO) according
to the manufacturer’s instructions. The DNA library was prepared using the Pacific Biosciences 20-kb
library preparation protocol and size selection with a 9-kb cutoff using BluePippin (Sage Sciences,
Beverly, MA). Sequencing was performed using the Pacific Biosciences RSII instrument using P6-C4
chemistry with a 360-min movie time and one single-molecule real-time sequencing (SMRT) cell. The
sequences were assembled and polished at The Norwegian Sequencing Centre (https://www.sequencing
.uio.no/) using HGAP v3 (Pacific Biosciences, SMRT Analysis Software v.2.3.0). Minimus2 from AMOS was
used to circularize contigs, and RS_Resequencing.1 software (Pacific Biosciences, SMRT Analysis Software
v.2.3.0) was used for correction of bases after circularization.
Selection of mutants with increased CAZ and CAZ-AVI MIC. Ten milliliters of an MP101 culture was
grown in MH broth at 37°C overnight and then centrifuged for 10 min at 4,000  g, and the pellet was
suspended in 1 ml MH broth. One hundred microliters was plated on MH agar containing increasing
concentrations of either CAZ alone or in combination with AVI up to 2 mg/liter. For CAZ-AVI, we utilized
the clinical ratio of 4:1, respectively. Colonies growing on the highest concentration were recovered and
grown in a fresh overnight culture (MH broth) and subsequently plated on concentrations of CAZ or
CAZ-AVI up to 32 mg/liter.
Antibiotic susceptibility testing. For MIC determination, single colonies were suspended in 0.9%
saline buffer to a 0.5 McFarland standard and further diluted 1:100 in MH broth. Fifty microliters of the
bacterial suspension was loaded onto in-house-designed and premade Sensititre microtiter plates (TREK
Diagnostic Systems/Thermo Fisher Scientific, East Grinstead, United Kingdom). The plates were incubated
for 20 h at 37°C. Antibiotic susceptibility testing was performed in duplicates.
blaOXA-48 sequencing and subcloning. After CAZ and CAZ-AVI exposure, plasmids were isolated
using a plasmid mini-purification kit (Qiagen, Germany), and mutations within blaOXA-48 were identified
by Sanger sequencing (BigDye 3.1 technology; Applied Biosystems, CA) using preOXA-48 primers (61).
For a functional resistance profile, the native and mutated blaOXA-48 genes were cloned in the
pCR-blunt II-TOPO vector (Invitrogen, CA) and expressed in E. coli TOP10 (Invitrogen, CA). The PCR
product was obtained by Phusion High Fidelity PCR mastermix with High Fidelity buffer (New England
Biolabs, MA) and preOXA-48 primers (61). Transformants were selected on LB agar plates containing 50
or 100 mg/liter ampicillin. Insertion size was verified by Sanger sequencing using M13 forward (5=-GTA
AAACGACGGCCAG-3=) and reverse (5=-CAGGAAACAGCTATGAC-3=) primers.
Recombinant enzyme construction, expression, and purification. In order to construct OXA-48:
P68A and OXA-48:P68A,Y211S, site-directed mutagenesis of blaOXA-48 in a pDEST17 vector was performed
using the QuikChange II site-directed mutagenesis kit (Agilent Biosciences, Santa Clara, CA) (64, 65).
XL1-Blue competent cells were heat shock transformed with the constructed DNA. Point mutations were
verified by Sanger sequencing using T7 primers, as described above. OXA-48 expression and purification
were done as described previously (51, 52). For the mutants, expression was performed in Rosetta
2(DE3)/pLysS. In general, cultures were grown to log phase in Terrific broth supplemented with ampicillin
(100 mg/liter) at 37°C and 180 rpm. Enzyme expression was induced with 0.1 mM IPTG (isopropyl--D-
thiogalactopyranoside) and performed at 15°C and 180 rpm overnight. Harvested cells were sonicated,
and recombinant proteins were purified as described previously (64).
Thermostability. Fluorescence-based protein thermostability was determined for OXA-48, OXA-48:
P68A, and OXA-48:P68A,Y211S in an MJ minicycler (Bio-Rad) across a temperature gradient of 25 to 60°C
(at a heating rate of 1°C per min). Thermostability was determined in 50 mM HEPES (VWR, PA) at pH 7.5
supplemented with 50 mM potassium sulfate (Honeywell, NC) using 0.2 mg/ml protein and 5 SYPRO
orange (Sigma-Aldrich, St. Louis, MO). The excitation and emission wavelengths of SYPRO orange are 470
and 570 nm, respectively. The melting temperatures were determined as the inflection point of the
melting transition found from the first derivative. All experiments were performed in triplicates.
Steady-state enzyme kinetics. The Km and kcat for recombinantly expressed OXA-48, OXA-48:P68A,
and OXA-48:P68A,Y211S were determined under steady-state conditions for ampicillin (Δ 
820 M1 cm1, 232 nm, 1 nM), piperacillin (Δ  820 M1 cm1, 235 nm, 1, 10, and 100 nM for
OXA-48, OXA-48:P68A, and OXA-48:P68A,Y211S, respectively), nitrocefin (Δ  17,400 M1 cm1, 482 nm,
0.75 nM), CAZ (Δ  9,000 M1 cm1, 260 nm, 150 nM), cefepime (Δ  10,000 M1 cm1, 260 nm,
1 nM), imipenem (Δ  9,000 M1 cm1, 300 nm, 150 nM), and meropenem (Δ  6,500 M1 cm1,
300 nm, 150 nM) by measuring the initial enzymatic reaction rate. The half-maximal inhibitory concen-
trations (IC50) for AVI and tazobactam were obtained after incubation of recombinant enzymes (0.75 nM)
with inhibitors for 5 min at 25°C. Nitrocefin (20 M) was utilized as the reporter substrate, and the initial
enzymatic reaction rate was measured at 482 nm. All determinations were performed at least in
duplicates at a final assay volume of 100 l. For nitrocefin-dependent reactions, 96-well plates (Thermo
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Fisher Scientific, Roskilde, Denmark) were utilized. For all the substances, UV-transparent 96-well plates
(Corning, Kennebunk, ME) were used. All test results were obtained at 25°C and in 0.1 M phosphate buffer
(pH 7.0) supplemented with 50 mM NaHCO3 (Sigma-Aldrich, St. Louis, MO). Calculations were performed
by using GraphPad Prism 7.0 (GraphPad Software, Inc.).
Crystallization, structure determination, and molecular modeling. OXA-48:P68A was crystallized
by the sitting-drop method in 22% to 26% polyethylene glycol monomethyl ether 5000 (Sigma-Aldrich,
St. Louis, MO) and 0.1 M BIS-Tris-propane buffer (Sigma-Aldrich, St. Louis, MO) at pH 6.5 to 7.5 at 4°C.
Crystals were soaked for some seconds in CAZ (saturated) or AVI (saturated) in cryoprotector, which was
in mother lipid and 10% ethylene glycol (Sigma-Aldrich, St. Louis, MO, USA), followed by being
flash-cooled in liquid nitrogen. Diffraction data were collected on BL14.1 and BL14.2 BESSY II, Berlin,
Germany, at 100 K at a wavelength of 0.9184 Å, and the diffraction images were indexed and integrated
using XDS (66). AIMLESS was used for scaling (67). During scaling, the final data sets were carefully
inspected (Table S1), where we aimed for high completeness: a CC1/2 of 0.5 in the outer resolution shell
and a mean above 1.0. Both structures were solved by molecular replacement with chain A of PDB no.
5QB4 (68) and the program Phenix 1.12 (69). Parts of the models were rebuilt using Coot (70). Figures
were prepared using PyMOL version 1.8 (Schrödinger). For OXA-48:P68A,Y211S, molecular modeling was
performed using Swiss-Model (71) and OXA-46:P68A as a template (PDB no. 6Q5F).
Fitness experiments. Two-milliliter overnight cultures were inoculated by picking single colonies
from LB agar plates and incubated for 24 h at 37°C and 700 rpm. Competitors were then mixed and
diluted 1:100 in a volumetric 1:1 ratio by passaging 5 l of each overnight culture into 990 l LB broth
in a 96-deep-well plate (VWR, PA). Initial (time 0 [T0]) and endpoint (time 24 h [T24]) CFU values for each
competitor were determined by selective plating on LB agar and LB agar containing 50 mg/liter
amoxicillin. Competitions were carried out at 37°C in at least triplicates. Relative fitness (w) was calculated
by determining the ratio between each pair of competitors using a Malthusian parameter and the
equation w  ln(AT24/AT0)/ln(BT24/BT0) (72), where A and B are the competing strains.
Plasmid sequencing. Plasmid DNA after CAZ and CAZ-AVI exposure was isolated as described
above, and fragment libraries were constructed by using the Nextera kit (Illumina, Little Chesterford,
United Kingdom) followed by 251-bp paired-end sequencing (MiSeq, Illumina). This was done according
to the manufacturer’s instructions. Paired-end sequence data were assembled using CLCbio’s Genomics
Workbench 8.0 (Qiagen, Aarhus, Denmark). Sequences were aligned against the native OXA-48 plasmid,
and mutations were identified using DNASTAR (DNASTAR, Madison, WI).
Plasmid stability. MP101 and MP103 were evolved under nonselective conditions in MH broth for
350 generations. Initially, 990 l MH broth was inoculated with 10 l of an overnight culture and
incubated for 12 h at 37°C and 700 rpm. Every 12 h, 10 l of the culture was transferred into 990 l MH
broth. Plasmid stability was tested after 0, 50, 100, 125, 140, 155, 165, 250, and 350 generations. For each
time point, an overnight culture was diluted 104 to 106 in 0.9% saline. One hundred microliters of each
concentration was plated on MH agar and incubated overnight at 37°C. Subsequently, 100 single
colonies were picked and streaked on MH agar containing 100 mg/liter ampicillin.
Data availability. Atom coordinates and structure factors for OXA-48:P68A and OXA-48:P68A-AVI
have been deposited in the Protein Data Bank (PDB no. 6Q5F and 6Q5B, respectively). The plasmid
sequence data (p50579417_3_OXA-48) are available in GenBank under accession no. CP033880. All other
relevant data are available within this article, the supplemental material, or from the corresponding
author upon request.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
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